مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma.
Normal view MARC view ISBD view

Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. [electronic resource]

By:
  • Roth, Gaël S
Contributor(s):
  • Macek Jilkova, Zuzana
  • Zeybek Kuyucu, Ayca
  • Kurma, Keerthi
  • Ahmad Pour, Séyédéh Tayébéh
  • Abbadessa, Giovanni
  • Yu, Yi
  • Busser, Benoit
  • Marche, Patrice N
  • Leroy, Vincent
  • Decaens, Thomas
Producer: 20180717Description: 2157-2165 p. digitalISSN:
  • 1538-8514
Subject(s):
  • Aminopyridines -- administration & dosage
  • Animals
  • Apoptosis -- drug effects
  • Carcinoma, Hepatocellular -- drug therapy
  • Cell Line, Tumor
  • Cell Proliferation -- drug effects
  • Disease Models, Animal
  • Humans
  • Imidazoles -- administration & dosage
  • Liver Cirrhosis -- drug therapy
  • Liver Neoplasms -- drug therapy
  • Niacinamide -- administration & dosage
  • Oncogene Protein v-akt -- antagonists & inhibitors
  • Phenylurea Compounds -- administration & dosage
  • Rats
  • Signal Transduction -- drug effects
  • Sorafenib
Online resources:
  • Available from publisher's website
In: Molecular cancer therapeutics vol. 16
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Log in to your account to post a comment.

Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma.

APA

Roth G. S., Macek Jilkova Z., Zeybek Kuyucu A., Kurma K., Ahmad Pour S. T., Abbadessa G., Yu Y., Busser B., Marche P. N., Leroy V. & Decaens T. (20180717). Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. : Molecular cancer therapeutics.

Chicago

Roth Gaël S, Macek Jilkova Zuzana, Zeybek Kuyucu Ayca, Kurma Keerthi, Ahmad Pour Séyédéh Tayébéh, Abbadessa Giovanni, Yu Yi, Busser Benoit, Marche Patrice N, Leroy Vincent and Decaens Thomas. 20180717. Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. : Molecular cancer therapeutics.

Harvard

Roth G. S., Macek Jilkova Z., Zeybek Kuyucu A., Kurma K., Ahmad Pour S. T., Abbadessa G., Yu Y., Busser B., Marche P. N., Leroy V. and Decaens T. (20180717). Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. : Molecular cancer therapeutics.

MLA

Roth Gaël S, Macek Jilkova Zuzana, Zeybek Kuyucu Ayca, Kurma Keerthi, Ahmad Pour Séyédéh Tayébéh, Abbadessa Giovanni, Yu Yi, Busser Benoit, Marche Patrice N, Leroy Vincent and Decaens Thomas. Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. : Molecular cancer therapeutics. 20180717.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site